ES2202130T3 - Uso de ciertos compuestos macrolidos para inducir diferenciacion condrogenica. - Google Patents

Uso de ciertos compuestos macrolidos para inducir diferenciacion condrogenica.

Info

Publication number
ES2202130T3
ES2202130T3 ES00931634T ES00931634T ES2202130T3 ES 2202130 T3 ES2202130 T3 ES 2202130T3 ES 00931634 T ES00931634 T ES 00931634T ES 00931634 T ES00931634 T ES 00931634T ES 2202130 T3 ES2202130 T3 ES 2202130T3
Authority
ES
Spain
Prior art keywords
group
hydrogen atom
hydroxy
alkyl
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES00931634T
Other languages
English (en)
Spanish (es)
Inventor
Fusako Nishigaki
Susumu Miyata
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Original Assignee
Fujisawa Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co Ltd filed Critical Fujisawa Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2202130T3 publication Critical patent/ES2202130T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
ES00931634T 1999-06-04 2000-05-31 Uso de ciertos compuestos macrolidos para inducir diferenciacion condrogenica. Expired - Lifetime ES2202130T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPQ078799 1999-06-04
AUPQ0787A AUPQ078799A0 (en) 1999-06-04 1999-06-04 New use

Publications (1)

Publication Number Publication Date
ES2202130T3 true ES2202130T3 (es) 2004-04-01

Family

ID=3814984

Family Applications (1)

Application Number Title Priority Date Filing Date
ES00931634T Expired - Lifetime ES2202130T3 (es) 1999-06-04 2000-05-31 Uso de ciertos compuestos macrolidos para inducir diferenciacion condrogenica.

Country Status (7)

Country Link
US (1) US6489340B1 (cg-RX-API-DMAC10.html)
EP (1) EP1183028B1 (cg-RX-API-DMAC10.html)
JP (1) JP2003501382A (cg-RX-API-DMAC10.html)
AU (1) AUPQ078799A0 (cg-RX-API-DMAC10.html)
DE (1) DE60004044T2 (cg-RX-API-DMAC10.html)
ES (1) ES2202130T3 (cg-RX-API-DMAC10.html)
WO (1) WO2000074665A2 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
AU2003901023A0 (en) * 2003-03-04 2003-03-20 Fujisawa Pharmaceutical Co., Ltd. New use
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
ITMI20051826A1 (it) * 2005-09-29 2007-03-30 Novachem S A Kit per la somministrazione parenterale di medicamenti
EP2182957A4 (en) * 2007-07-31 2012-07-18 Limerick Biopharma Inc PHOSPHORYLATED PYRONANALOGES AND CORRESPONDING METHODS

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE388724T1 (de) * 1998-01-08 2008-03-15 Univ Washington Methoden zur kontrolle der zelldifferenzierung und des zellwachstums durch verwendung eines fusionsproteins und eines wirkstoffes

Also Published As

Publication number Publication date
JP2003501382A (ja) 2003-01-14
AUPQ078799A0 (en) 1999-06-24
US6489340B1 (en) 2002-12-03
WO2000074665A3 (en) 2001-05-17
EP1183028B1 (en) 2003-07-23
WO2000074665A2 (en) 2000-12-14
DE60004044T2 (de) 2004-04-15
DE60004044D1 (de) 2003-08-28
EP1183028A2 (en) 2002-03-06

Similar Documents

Publication Publication Date Title
EP0581959B1 (en) Use of macrolide compounds for eye diseases
US6384073B1 (en) Use of macrolide compounds for treating glaucoma
EP1093371A1 (en) Use of fk506 and related macrolides in the manufacture of a medicament for treatment or prevention of pain
AU749475B2 (en) Medicinal compositions
WO1991019495A1 (en) Use of a macrolide compound such as fk 506 for manufacturing a medicament for treating idiopathic thrombocytopenic purpura and basedow's disease
US6333334B1 (en) Use of macrolide compounds for the treatment of ARDS
US6489340B1 (en) Macrolide compounds for inducing chondrogenic differentiation
AU687025B2 (en) Use of macrolides for the treatment of cerebral ischemia
GB2279006A (en) Treatment of amyotrophic lateral sclerosis
US5643901A (en) Medicament for treating idiopathic thrombocytopenic purpura
US20050143411A1 (en) Method for treating pulmonary disease
WO2000007594A1 (en) Use of il-2 inhibitors in the treatment of rheumatoid arthritis
ES et al. VERWENDUNG VON MAKROLIDEN ZUR BEHANDLUNG VON AKUTEN LUNGENVERLETZUNGEN UTILISATION DE MACROLIDES POUR LE TRAITEMENT DES LESIONS DES POUMONS
HK1012229B (en) Use of macrolides for the treatment of cerebral ischemia